Tagged with USA

USA In a recent virtual town hall meeting hosted by BIO, two key leaders from the US FDA laid out how their organisation has adjusted in the wake of the COVID-19 crisis, at what stage of development diagnostics and therapeutics for the virus are, and the pandemic’s long-term effects – both…

Korea After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND) approval from the FDA.   Dr Kyung Suk Kim, Corestem’s CEO, recently spoke to PharmaBoardroom to give an update on…

Coronavirus The BIO International Convention was held digitally in June 2020, bringing together over 7,000 participants from around the world. In an R&D-focused session titled “Whiplash! How Covid-19 Will Radically Change Biomedical R&D Across the Globe,” moderator Andy Marshall of Nature Biotechnology brought together experts in biotech, pharma innovation and research.…

Italy Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of Stemline Therapeutics.   The deal, said to be worth USD 677 million, was announced on 4 May 2020 and completed on 10 June. The acquisition of Stemline,…

USA As of 11 June 2020, there have been over two million confirmed cases of COVID-19 in the US and over 115,000 deaths, with the US having occupied the leading spot globally in terms of confirmed cases since late-March. While the pandemic has wreaked havoc across the entire country, advocates of…

USA Peter L Saltonstall, president and CEO of the US National Organization for Rare Disorders (NORD) shares the organization’s key priorities, what makes NORD a unique patient advocacy group in the US, prevailing access and affordability issues for American rare disease patients, and how the country should continue to incentivize a…

USA Three US country managers for European pharma mid-caps explain the challenges in setting up an American affiliate, as well as how best to capitalise on the abundant opportunities in the world’s biggest pharma market.   For Jorge Alderete, president Americas & SVP commercial operations at Danish firm ALK, “Market access…

Coronavirus At the 28 May 2020 IFPMA media briefing on COVID-19 vaccines, Pfizer chairman and CEO Dr Albert Bourla outlined why the US firm had decided to take a different tack to that of its rivals in developing a vaccine using the innovative but as yet unproven Messenger RNA (mRNA) technology…

USA Jose Antonio Moreno Toscano, CEO for the US affiliate of iconic French firm LFB shares the company’s journey in the US market and his insights for other European mid-caps looking to achieve success across the Atlantic.   The US market is not really a country market but a continental or…

USA Dr Gerard Anderson of Johns Hopkins University Bloomberg School of Public Health critiques the US response to the COVID-19 pandemic, before explaining how access and affordability in the US can be improved, and his outlook on the future of American public health.   To some extent, we are the poster…

Coronavirus In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He explained the firm’s collaboration with US research group BARDA and underscored that Sanofi is committed to bringing vaccines to all…

USA Jorge Alderete, president of ALK Americas, recently spoke to PharmaBoardroom about his 20+ years with the Danish mid-cap, the challenges in communicating the USA’s challenging market access environment to a European HQ, and why new models of patient-doctor interaction and medical distribution are crucial to ALK’s future success.   A…